1. Male or female subjects of 18 years to 60 years both inclusive <br/ >2. Subject and/or his/her legally accepted representative willing to give written informed <br/ >consent. <br/ >3. Subjects with laboratory confirmation of infection with SARS-CoV-2 by positive RTPCR <br/ >(within 48 hours prior to randomization). <br/ >4 Subjects having mild grade of COVID-19 as per MoH & FW guidelines on â??Clinical <br/ >Management Protocol: COVID-19â?? as updated from time to time. <br/ >a. Mild COVID-19: Patients with uncomplicated upper respiratory tract infection, <br/ >may have mild symptoms such as fever, cough, sore throat, nasal congestion, <br/ >malaise, headache, without evidence of breathlessness or hypoxia (normal <br/ >saturation). (Time for symptom onset and baseline should be no more than 7 <br/ >days).

1. Male or female subjects of 18 years to 60 years both inclusive <br/ >2. Subject and/or his/her legally accepted representative willing to give written informed <br/ >consent. <br/ >3. Subjects with laboratory confirmation of infection with SARS-CoV-2 by positive RTPCR <br/ >(within 48 hours prior to randomization). <br/ >4 Subjects having mild grade of COVID-19 as per MoH & FW guidelines on â??Clinical <br/ >Management Protocol: COVID-19â?? as updated from time to time. <br/ >a. Mild COVID-19: Patients with uncomplicated upper respiratory tract infection, <br/ >may have mild symptoms such as fever, cough, sore throat, nasal congestion, <br/ >malaise, headache, without evidence of breathlessness or hypoxia (normal <br/ >saturation). (Time for symptom onset and baseline should be no more than 7 <br/ >days).

1. Male or female subjects of 18 years to 60 years both inclusive <br/ >2. Subject and/or his/her legally accepted representative willing to give written informed <br/ >consent. <br/ >3. Subjects with laboratory confirmation of infection with SARS-CoV-2 by positive RTPCR <br/ >(within 48 hours prior to randomization). <br/ >4 Subjects having mild grade of COVID-19 as per MoH & FW guidelines on â??Clinical <br/ >Management Protocol: COVID-19â?? as updated from time to time. <br/ >a. Mild COVID-19: Patients with uncomplicated upper respiratory tract infection, <br/ >may have mild symptoms such as fever, cough, sore throat, nasal congestion, <br/ >malaise, headache, without evidence of breathlessness or hypoxia (normal <br/ >saturation). (Time for symptom onset and baseline should be no more than 7 <br/ >days).

1. Male or female subjects of 18 years to 60 years both inclusive <br/ >2. Subject and/or his/her legally accepted representative willing to give written informed <br/ >consent. <br/ >3. Subjects with laboratory confirmation of infection with SARS-CoV-2 by positive RTPCR <br/ >(within 48 hours prior to randomization). <br/ >4 Subjects having mild grade of COVID-19 as per MoH & FW guidelines on â??Clinical <br/ >Management Protocol: COVID-19â?? as updated from time to time. <br/ >a. Mild COVID-19: Patients with uncomplicated upper respiratory tract infection, <br/ >may have mild symptoms such as fever, cough, sore throat, nasal congestion, <br/ >malaise, headache, without evidence of breathlessness or hypoxia (normal <br/ >saturation). (Time for symptom onset and baseline should be no more than 7 <br/ >days).